Ever since Anavex Life Sciences Corp (OTCMKTS:AVXL) unveiled the finding of a new report, its stock price has been moving up remarkably. Friday was no less an exception when the stock price of the company moved back in the green to settle at $0.330, higher by close to 14%. The average share trade volume of the company recorded on the day stood at 1.89 million shares.
Sigma-1 receptor activation
The most relevant press release by the company was published during late April when it noted the review on the company’s Sigma-1 receptor agonists that appeared in Neuroscience Letters, a Scientific journal.
The review highlighted the real-time study that showed the effectiveness of sigma-1 receptor in overcoming the devastating effects of microglial inflammation. On activation, sigma-1 receptor helps in reducing the negative response, which are caused by Chronic microglia that leads to neurodegenerative diseases, including Alzheimer’s disease and brain injury.
Establishes the fact For ANAVEX
Anavex Life Sciences Corp (OTCMKTS:AVXL) commented that the findings published in the journal were inspiring and helped establish the fact that the sigma-1 receptor has power to control the neurodegenerative diseases. The review published in the journal further signifies the role of Anavex Life Sciences Corp (OTCMKTS:AVXL)’s sigma-1 receptor agonists, including ANAVEX 2-73, which is presently put under a Phase 2a clinical study to treat Alzheimer’s disease. The company drew important indications from the review that sigma-1 receptor activity could be accelerated through agonists, which in turn, will help nullify the impact of neuro inflammation and other associated symptoms.
The company found the report findings convincing to reach a conclusion that its work on activating sigma-1 receptor bears a lot of importance. The company’s CEO Christopher U. Missling too expressed content over the findings and was confident that ANAVEX 2-73 will successfully minimize the impact of microglia inflammation.
